Safety Study of GCS-100 to Treat Chronic Kidney Disease

NCT ID: NCT01717248

Last Updated: 2013-06-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 29 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2013-06-30

Brief Summary

The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.

Conditions

Chronic Kidney Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

GCS-100

GCS-100 will be administered once weekly by a ten minutes injection.

Group Type: EXPERIMENTAL

GCS-100

Intervention Type: DRUG

GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).

Interventions

GCS-100

GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1. Subject is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.

2. Subject is male or female, aged >=18 and <= 75. Patients older than 75 y/o will be included at the request of the investigator and at the discretion of the Medical Monitor .

3. Adult patients with chronic kidney disease for longer than 12 months and stable in the opinion of the investigator for the past 3 months 4. Systolic blood pressure <=160 mm Hg and >= 90 mm Hg on 2 readings. Diastolic blood pressure <= 100 mm Hg and >= 40 mm Hg on 2 readings during at least one of the screening visits.

5. Subject is willing to practice birth control. 6. Subject is willing and able to comply with all protocol requirements. 7. Subject has a measureable level of galectin-3 concentration in plasma at any time prior to entry.

8. Subject has a glomerular filtration rate between 15-45 mL/min/1.73 m2 determined using the CKD-EPI equation (see section 3.6.1) 9. Subject's has clinical laboratory values of:

1. Hemoglobin ≥9 g/dL

2. Total bilirubin ≤ 1.5 X Institutional Upper Limit of Normal (IULN)

3. AST and/or ALT ≤ 2.5 X the upper limit of normal 10. Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least 1 year) and male subjects with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the study period.

Exclusion Criteria

1. Subjects who have had treatment with an experimental (unlicensed) drug within 4 weeks or ≤ 5 half-lives prior to treatment with GCS 100.

2. Subjects with kidney disease due to systemic lupus erythematosus (regardless of whether active or in remission), any form of vasculitis (regardless of whether active or in remission), IgA nephropathy, multiple myeloma, polycystic kidney disease, untreated obstructed nephropathy or any other causes that in the opinion of the investigator may put the subject at an increased risk

3. Subject is expected to start renal replacement therapy of any kind within 6 months after enrollment

4. Subjects with previous solid organ transplant

5. Subject is undergoing treatment with immunosuppression agents except for topical agents or inhaled steroids when conditions are chronic and stable.

6. Subject with know history of cancer within the past 5 years prior to enrollment excluding non-melanoma skin cancer that is not being actively treated

7. Subject has a known history of human immunodeficiency virus infection, active hepatitis C, active hepatitis B, or prior history of infection with hepatitis B (HBcAb positive). Medical Monitor may approve if adequate hepatic function has been documented for patients without evidence of cirrhosis for subjects with HCV or prior history of hepatitis B, including, but not limited to liver biopsy.

8. Subject has a clinically relevant active infection and/or a serious co-morbid medical condition such as recent myocardial infarction (within the last 6 months), unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.

9. Subject had major surgery within 4 weeks prior to Study Day 1.

10. If female, subject is pregnant or breastfeeding.

11. Subject has a concomitant disease or condition, including laboratory abnormalities, which in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

La Jolla Pharmaceutical Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pablo Pergola, MD

Role: PRINCIPAL_INVESTIGATOR

Renal Associaties PA, Research Division

Geoffrey Block, MD

Role: PRINCIPAL_INVESTIGATOR

Denver Nephrologists, PC

Bhupinder Singh, MD

Role: PRINCIPAL_INVESTIGATOR

Southwest Clinical Research Institute, LLC

George Fadda, MD

Role: PRINCIPAL_INVESTIGATOR

California Institute of Renal Research

Locations

Southwest Clinical Research Institute

Tempe, Arizona, United States

California Institue of Renal Research

La Mesa, California, United States

Denver Nephrologists, PC

Denver, Colorado, United States

Renal Associates PA / Research Division

San Antonio, Texas, United States

Countries

United States

Other Identifiers

GCS-100-CS-4001

Identifier Type: -

Identifier Source: org_study_id